PDE5 Inhibitors Enhance Celecoxib Killing in Multiple Tumor Types
- 9 October 2014
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 230 (5) , 1115-1127
Abstract
The present studies determined whether clinically relevant phosphodiesterase 5 (PDE5) inhibitors interacted with a clinically relevant NSAID, celecoxib, to kill tumor cells. Celecoxib and PDE5 inhibitors interacted in a greater than additive fashion to kill multiple tumor cell types. Celecoxib and sildenafil killed ex vivo primary human glioma cells as well as their associated activated microglia. Knock down of PDE5 recapitulated the effects of PDE5 inhibitor treatment; the nitric oxide synthase inhibitor L‐NAME suppressed drug combination toxicity. The effects of celecoxib were COX2 independent. Over‐expression of c‐FLIP‐s or knock down of CD95/FADD significantly reduced killing by the drug combination. CD95 activation was dependent on nitric oxide and ceramide signaling. CD95 signaling activated the JNK pathway and inhibition of JNK suppressed cell killing. The drug combination inactivated mTOR and increased the levels of autophagy and knock down of Beclin1 or ATG5 strongly suppressed killing by the drug combination. The drug combination caused an ER stress response; knock down of IRE1α/XBP1 enhanced killing whereas knock down of eIF2α/ATF4/CHOP suppressed killing. Sildenafil and celecoxib treatment suppressed the growth of mammary tumors in vivo. Collectively our data demonstrate that clinically achievable concentrations of celecoxib and sildenafil have the potential to be a new therapeutic approach for cancer. J. Cell. Physiol. 230: 1115–1127, 2015. © 2014 Wiley Periodicals, Inc., A Wiley CompanyKeywords
Funding Information
- National Institutes of Health (R01-CA141704, R01-CA150214, R01-DK52825, R01-CA61774)
- NIH-NCI Massey Cancer Center (CA016059)
- NCI Cancer Core (P30 CA016059)
This publication has 71 references indexed in Scilit:
- Obatoclax and Lapatinib Interact to Induce Toxic Autophagy through NOXAMolecular Pharmacology, 2012
- Celecoxib Promotes c-FLIP Degradation through Akt-Independent Inhibition of GSK3Cancer Research, 2011
- Chemoprevention in familial adenomatous polyposisBest Practice & Research Clinical Gastroenterology, 2011
- ERK/Ribosomal S6 Kinase (RSK) Signaling Positively Regulates Death Receptor 5 Expression through Co-activation of CHOP and Elk1Journal of Biological Chemistry, 2010
- Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunctionProceedings of the National Academy of Sciences, 2010
- cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP ActionPharmacological Reviews, 2010
- Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-De novo Ceramide-PP2A-Reactive Oxygen Species–Dependent Signaling PathwayCancer Research, 2010
- Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3βJournal of Biological Chemistry, 2008
- OSU-03012 Stimulates PKR-Like Endoplasmic Reticulum-Dependent Increases in 70-kDa Heat Shock Protein Expression, Attenuating Its Lethal Actions in Transformed CellsMolecular Pharmacology, 2008
- Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancerAnnals of Oncology, 2006